Incyte Corporation - Common Stock (NQ:INCY)

113.31 -2.40 (-2.07%)

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

29 30 Next >

7 Cash-Rich Stocks to Buy for Peace of Mind ↗

November 04, 2022

It pays to hold cash-rich stocks that can weather any storm because of their financial strength. Investors may want to watch these seven.

Via InvestorPlace

2 Biotech Stocks That Could Make You Richer ↗

November 04, 2022

Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.

Via The Motley Fool

More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting

November 03, 2022

From Incyte

Via Business Wire

Recap: Incyte Q3 Earnings ↗

November 01, 2022

Incyte (NASDAQ:INCY) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Incyte missed estimated earnings by...

Via Benzinga

Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

November 01, 2022

From Incyte

Via Business Wire

Expert Ratings for Incyte ↗

October 18, 2022

Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:

Via Benzinga

MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings ↗

September 29, 2022

Via Benzinga

Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

October 19, 2022

From Incyte

Via Business Wire

Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm' ↗

October 17, 2022

Via Benzinga

Incyte to Report Third Quarter Financial Results

October 11, 2022

From Incyte

Via Business Wire

2 Cathie Wood Stocks That Are Beating the Market This Year ↗

October 07, 2022

One is doing much better than the other year to date, but they both have solid prospects ahead.

Via The Motley Fool

Incyte Q2 Earnings Beat Estimates But Tightens FY22 Jakafi Sales Guidance ↗

August 02, 2022

Via Benzinga

Recap: Incyte Q2 Earnings ↗

August 02, 2022

Incyte (NASDAQ:INCY) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Expert Ratings for Incyte ↗

July 28, 2022

Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:

Via Benzinga

Incyte Names New Member to Its Board of Directors

October 04, 2022

From Incyte

Via Business Wire

Incyte Acquires Villaris Therapeutics, Deepening Portfolio For Immune-Mediated Dermatologic Diseases ↗

October 03, 2022

Via Benzinga

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

October 03, 2022

From Incyte

Via Business Wire

Death Cross Looms Over Incyte Investors ↗

September 22, 2022

If history is any guide, there may be trouble ahead for shares of Incyte (NASDAQ:INCY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Via Benzinga

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary ↗

September 15, 2022

Via Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary ↗

August 26, 2022

Via Benzinga

Incyte Gets FDA Nod For Hematologic Malignancies Candidate ↗

August 26, 2022

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ: INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with...

Via Benzinga

Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement

August 26, 2022

From Incyte

Via Business Wire

Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress

August 24, 2022

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conference

August 23, 2022

From Incyte

Via Business Wire

10 Most Oversold Stocks To Buy In August 2022 ↗

August 10, 2022

Looking for some oversold stocks to buy? Here's the 10 most oversold on the S&P 500 for August 2022.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022 ↗

August 03, 2022

Via Benzinga

Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled ↗

August 02, 2022

Jakafi sales beat and the company raised its guidance. But another drug fell short.

Via Investor's Business Daily

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗

August 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

August 02, 2022

From Incyte

Via Business Wire

Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗

July 31, 2022

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...

Via Benzinga

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.